Inactive Instrument

News Atrinsic, Inc. Other OTC

Equities

US04964C2089

End-of-day quote Other OTC Other stock markets
- ^USD	-

May. 01	Protagenic Therapeutics, Inc. Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial	CI
Apr. 01	Protagenic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Protagenic Therapeutics, Inc. Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial	May. 01	CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders	Mar. 27	CI
Protagenic Therapeutics, Inc.	Mar. 21	AQ
Protagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders	Feb. 14	AQ
Protagenic Therapeutics Achieves First Clinical Safety Milestone with Its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders	Feb. 13	CI
Wall Street Set to Open Slightly Higher Tuesday; Annual Inflation Declines to 3.1%	Dec. 12	MT
Protagonist Therapeutics, Inc. Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals	Dec. 12	CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
PROTAGENIC THERAPEUTICS, INC.NEW Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-31	AQ
Protagenic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Reverse Split: 1 of 4	23-03-22	FA
PROTAGENIC THERAPEUTICS, INC.NEW : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	23-03-22	AQ
Protagenic Therapeutics, Inc. Appoints Timothy R. Wright as a Class I Director	22-11-29	CI
PROTAGENIC THERAPEUTICS, INC.NEW : Submission of Matters to a Vote of Security Holders, Other Events (form 8-K)	22-11-29	AQ
PROTAGENIC THERAPEUTICS, INC.NEW Management's Discussion and Analysis of Financial Condition and Results of Operation (form 10-Q)	22-11-14	AQ
Protagenic Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
PROTAGENIC THERAPEUTICS, INC.NEW : Other Events (form 8-K)	22-09-02	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Atrinsic, Inc. Other OTC

Equities

US04964C2089

Summary

Filters